H.C. Wainwright Reiterates Buy Rating on Bright Minds Biosciences Inc. (DRUG)

June 2, 2026 6:57 AM

H.C. Wainwright analyst Pat Trucchio reiterated a Buy rating and $145.00 price target on Bright Minds Biosciences Inc. (NASDAQ: DRUG).The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found